Microdosing tirzepatide and Zepbound dosing charts Tirzepatide sold as Zepbound for obesity was studied in specific doses
A recent retrospective cohort also observed that, even in overweight patients without diabetes, the risk of primary open-angle glaucoma and ocular hypertension were significantly lower in the GLP-1RA group at both 3 and 5 years of follow-up (Vasu et al., 2025), suggesting the benefit of GLP-1RAs in the eye as an independent factor apart from blood glucose control
GLP-RT is commonly used in laboratory research to investigate signaling between three metabolic hormone receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
2 Currently approved GLP-1 drugs for chronic weight management include Saxenda, which is a once-daily injection, and Wegovy and Zepbound, which are once-weekly injections
Visceral abdominal fat and associated cardiometabolic risk
When comparing cell sources, trade-offs in potency and safety emerge
